PCOS and Fertility — How It Affects Conception and What Works (2026)

PCOS is diagnosed using the Rotterdam criteria, which require two of three features: irregular or absent ovulation, clinical or biochemical signs of excess androgens, and polycystic ovarian morphology on ultrasound. The 2023 international guideline reaffirmed those criteria.

Two of three matters more than it sounds. It means PCOS is not one presentation but several, and two women with the same diagnosis can have very different problems. One may not ovulate at all; another may ovulate regularly and have a diagnosis driven by androgens and ultrasound appearance.

• PCOS is diagnosed on the Rotterdam criteria: two of three from irregular ovulation, excess androgens, and polycystic ovarian morphology.
• The obstacle to conception in PCOS is usually ovulation, not egg supply.
• The 2023 International Evidence-based Guideline makes letrozole first-line for ovulation induction, ahead of clomiphene citrate.
• Metformin is recommended primarily for metabolic features and has greater efficacy than inositol, whose clinical benefits are limited.

The 2023 guideline also introduced AMH into the diagnostic process, reflecting that a high follicle count shows up in the blood as well as on a scan.

Principally through ovulation. The characteristic problem in PCOS is that follicles develop but do not reliably release an egg, so cycles become irregular or stop. Where ovulation is not happening, conception cannot happen either.

This is a more hopeful mechanism than it first appears. The obstacle is a process that can often be restarted with medication, rather than an absence of eggs — women with PCOS typically have a plentiful follicle pool, which is the source of the diagnosis in the first place.

It is also why the treatment ladder for PCOS starts several rungs below IVF. The first question is not which assisted technique to use, but whether ovulation can be induced.

Irregular cycles also make timing difficult in a way that compounds the problem. Where ovulation is unpredictable, the fertile window is unpredictable, so even cycles in which an egg is released can be missed. Restoring some regularity helps on both counts at once.

A PCOS diagnosis does not mean you will need treatment to conceive. Many women with PCOS ovulate some of the time and conceive without intervention, particularly where cycles are irregular rather than absent. The diagnosis describes a pattern, not a prognosis.

• Can PCOS Be Cured Naturally? What Actually Changes the Outcome
• Ozempic and Fertility: What to Know Before Trying to Conceive
• Ovulation Induction: Process and Success Rates
• What Is Diminished Ovarian Reserve? What the Tests Do and Do Not Tell You (2026)
• Fertility and PCOS Hair Loss Connection
• Clomid for Women: Uses and Side Effects
• Endometriosis and IVF: What the Evidence Says About Surgery First

The features that make up the diagnosis are irregular or absent periods, signs of excess androgens such as acne or unwanted hair growth, and a characteristic appearance of the ovaries on ultrasound. Two of the three are required.

• Irregular, infrequent or absent periods.
• Acne, oily skin, or hair growth in a male pattern.
• Hair thinning on the scalp.
• Multiple small follicles on ovarian ultrasound.

Because only two of three features are needed, the presentation varies widely. A woman with regular cycles can still have PCOS on the basis of androgen signs and ultrasound appearance, and she has a different fertility picture from someone who is not ovulating at all.

This is why a PCOS diagnosis on its own does not tell you what your treatment will be. The relevant question is which of the three features you have, and specifically whether ovulation is happening.

Letrozole. The 2023 International Evidence-based Guideline recommends letrozole as the first-line pharmacological treatment for ovulation induction in anovulatory women with PCOS and no other infertility factors, on the grounds of superior ovulation and live birth rates compared with clomiphene citrate.

This matters because clomiphene was the standard for decades and is still widely prescribed first. If you have been started on clomiphene without discussion, it is reasonable to ask why, since the current guideline puts letrozole ahead of it.

Clomiphene has not been abandoned. The guideline positions clomiphene combined with metformin, along with gonadotrophins or ovarian surgery, as second-line options where first-line treatment does not work.

So the ladder has a clear shape: letrozole first; clomiphene with metformin, gonadotrophins or ovarian surgery as second-line; assisted reproduction beyond that. Knowing where you are on it is more useful than knowing the name of any single drug, because it tells you what should have been tried already and what comes next.

Ovulation induction is monitored with scans, and that monitoring is not optional. The same responsiveness that makes PCOS treatable also makes over-response possible, and a cycle that recruits several follicles carries a multiple pregnancy risk that needs managing rather than discovering.

The 2023 guideline recommends metformin primarily for the metabolic features of PCOS rather than as a standalone fertility treatment, and notes it has greater efficacy than inositol, whose clinical benefits are described as limited.

Metformin is not therefore an alternative to letrozole. The guideline suggests considering it alongside letrozole or clomiphene rather than instead of them, which is a different proposition from the way it is sometimes presented.

The point about inositol is worth stating plainly because it is heavily marketed to women with PCOS. The guideline's position is that its clinical benefits are limited and that metformin outperforms it.

This matters commercially as well as clinically. Inositol is sold widely as a PCOS supplement, often at a price comparable to a prescription, and often to women who have not been offered the treatments the guideline actually recommends. Being sold a supplement instead of being started on letrozole is a poor exchange.

None of that makes inositol harmful, and some women take it alongside prescribed treatment without issue. The distinction worth holding is between something with limited clinical benefit and something the guideline puts first, and not confusing the order of those two.

IVF sits further down the ladder, after ovulation induction has been tried. Women with PCOS often respond strongly to stimulation, which is an advantage for egg numbers and a risk for ovarian hyperstimulation syndrome.

That risk shapes protocol choice. The antagonist protocol is generally preferred in PCOS, because it carries a substantially lower incidence of OHSS with no loss of ongoing pregnancy in this group. Our explanation of what ovarian hyperstimulation syndrome involves covers the condition.

So a PCOS diagnosis does not make IVF harder in terms of egg supply. It makes the safety planning around stimulation more important, which is a question for the clinic rather than a reason for pessimism.

The terms are used interchangeably in India, and PCOD is the older label. Clinically the diagnosis being described is the same condition, assessed against the Rotterdam criteria.

Some sources present PCOD as a milder condition and PCOS as a more severe one. That distinction is not part of the diagnostic criteria, and it is not a difference the 2023 guideline recognises. We look at the terminology in more detail in PCOD versus PCOS.

What does vary is severity within the diagnosis, which is a matter of which features you have and how pronounced they are — not of which of the two names your report uses.

If you have been told you have PCOD and are trying to work out whether that is better or worse news than PCOS, the answer is that it is the same news. What determines your situation is whether you are ovulating, what your androgen levels look like, and how your metabolic markers sit — not the label on the report.

The most useful first question is whether you are ovulating, because the whole treatment ladder branches on the answer. It is established with cycle tracking and blood tests, not inferred from the diagnosis itself.

• Am I ovulating, and how was that established?
• Which of the Rotterdam features do I actually have?
• If treatment is needed, why this drug rather than letrozole first?
• How will the cycle be monitored, and what is the multiple pregnancy risk?

If you are prescribed clomiphene as a first step, ask why letrozole was not chosen. There may be a good reason specific to you. But the 2023 guideline puts letrozole first, and a prescription that departs from current guidance should come with an explanation rather than by default.